Cyclopharm: Cyclopharm (ASX:CYC) Technegas Phase 3 Trial meets primary endpoint
28 Sep 2020 - Cyclopharm Limited (ASX:CYC) Managing Director and CEO James McBrayer provides an update on the company's US Phase 3 trial for Technegas, and USFDA approval process timeline, with commercial sales expected in the US for 2021.
Read full article »
Cyclopharm is a Canada-based radiopharmaceutical company that develops and commercializes medicine for the treatment of cramps, tooth pain and irritable bowel syndrome.
Read more